OBE2109
Showing 1 - 7 of 7
Uterine Fibroids, Heavy Menstrual Bleeding Trial in Worldwide (OBE2109, Placebo to match OBE2109, Placebo to match Add-back)
Completed
- Uterine Fibroids
- Heavy Menstrual Bleeding
- OBE2109
- +3 more
-
Chino, California
- +95 more
Mar 3, 2021
Uterine Fibroids, Heavy Menstrual Bleeding Trial in United States (OBE2109, Placebo to match OBE2109, Placebo to match Add-back)
Completed
- Uterine Fibroids
- Heavy Menstrual Bleeding
- OBE2109
- +3 more
-
Birmingham, Alabama
- +115 more
Jun 1, 2021
Endometriosis Trial in Worldwide (75 mg linzagolix tablet, 200 mg linzagolix tablet, Placebo tablet to match 75 mg linzagolix
Active, not recruiting
- Endometriosis
- 75 mg linzagolix tablet
- +5 more
-
Dothan, Alabama
- +46 more
Jan 12, 2023
Endometriosis Trial in Canada, Puerto Rico, United States (75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule
Terminated
- Endometriosis
- 75 mg linzagolix tablet
- +5 more
-
Little Rock, Arkansas
- +24 more
Dec 10, 2021